Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Short-term Investments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Short-term Investments for 6 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 63.86% to $61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.9 million through Dec 2025, down 63.86% year-over-year, with the annual reading at $61.9 million for FY2025, 63.86% down from the prior year.
  • Short-term Investments for Q4 2025 was $61.9 million at Lexicon Pharmaceuticals, down from $66.3 million in the prior quarter.
  • The five-year high for Short-term Investments was $274.3 million in Q2 2024, with the low at $61.9 million in Q4 2025.
  • Average Short-term Investments over 3 years is $157.1 million, with a median of $151.0 million recorded in 2023.
  • The sharpest move saw Short-term Investments surged 224.14% in 2024, then crashed 70.38% in 2025.
  • Over 3 years, Short-term Investments stood at $147.6 million in 2023, then grew by 16.09% to $171.3 million in 2024, then crashed by 63.86% to $61.9 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $61.9 million, $66.3 million, and $117.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.